New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 27, 2012
16:15 EDTTM, BCDS, DIOD, VVUS, QCOR, JCPOn The Fly: Closing Wrap
Stocks on Wall Street spent almost the entire session in negative territory but the averages recovered most of their losses in the last hour of trading. Headlines from Washington late in the trading day indicated the House of Representatives plans a session for Sunday evening to discuss the fiscal cliff. After opening lower the averages fell to their worst levels just after midday and were trading near those levels before moving sharply higher, and eventually erasing almost all of their losses, during the final 90 minutes of trading... ECONOMIC EVENTS: In the U.S., weekly jobless claims fell 12,000 to 350,000, compared to expectations for claims to remain relatively flat with the prior week. Sales of new homes rose 4.4% in November from October to a seasonally adjusted annual rate of 377,000, beating expectations. Consumer confidence fell to its lowest level since August with a 65.1 reading for December, versus expectations for a 70.0 figure. This morning, Senate Majority Leader Harry Reid warned that there may not be enough time left to reach a budget deal and that the U.S. appears destined to head over the fiscal cliff. However, late day optimism took hold based on plans for the House to reconvene this weekend... COMPANY NEWS: U.S. listed shares of Toyota Motor (TM) gained $2.18, or 2.41%, to $92.54 after the company agreed to a settlement valued over $1B related to previous recalls over claims of accelerator pedal problems... MAJOR MOVERS: Among the notable gainers was BCD Semiconductor (BCDS), which rose $3.43, or 86.18%, to $7.41 after agreeing to be acquired by Diodes (DIOD) for $8.00 per U.S. listed share. Shares of Diodes also gained 23c, or 1.36%, to $17.14. Also higher were shares of VIVUS (VVUS), up 51c, or 3.88%, to $13.67 after the company's CEO was quoted by Financial Times as saying he foresees the potential for using direct-to-consumer advertising and a larger scale sales force to market its Qsymia weight-loss drug. Among the noteworthy losers was Questcor Pharmaceuticals (QCOR), down $2.12, or 7.09%, to $27.78 after the circulation of a Blue Cross/Blue Shield of Michigan document related to coverage of the company's Acthar Gel. Also lower were shares of and J.C. Penney (JCP), down $1.23, or 5.93%, to $19.52 after being mentioned by The Wall Street Journal as a retailer that may face a particularly challenging and important year in 2013... INDICES: The Dow was down 18.28, or 0.14%, to 13,096.31; the Nasdaq was down 4.25, or 0.14%, to 2,985.91; and the S&P 500 was down 1.74, or 0.12%, to 1,418.09.
News For TM;BCDS;DIOD;VVUS;QCOR;JCP From The Last 14 Days
Check below for free stories on TM;BCDS;DIOD;VVUS;QCOR;JCP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
April 8, 2014
10:03 EDTQCOROn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:41 EDTQCORMallinckrodt downside risk minimal from current levels, says Piper Jaffray
Subscribe for More Information
07:20 EDTQCORMallinckrodt shares pressured on lingering Acthar concerns, says Jefferies
Jefferies says shares of Mallinckrodt (MNK) sold off yesterday despite "significant accretion potential" from the Questcor (QCOR) acquisition due to lingering Acthar concerns relating to generic competition and the ongoing U.S. Attorney's investigation. The firm says its accretion math suggests $3 in earnings per share by FY15, which it feels justifies a $75-$85 share range for Mallinckrodt. It keeps a Buy rating on the stock with a $77 price target.
07:17 EDTTMChina car sales up 9% as curbs spark early purchases, Bloomberg says
Subscribe for More Information
07:14 EDTTMGM SUVs earn top scores among rivals in crash test, Bloomberg says
The Insurance Institute for Highway Safety said GM's (GM) Chevrolet Equinox and GMC Terrain earned the highest scores among mid-size sport-utility cars in a test made to simulate one of the deadliest kinds of front-end crashes, according to Bloomberg, citing a statement from IIHS's Chief Research Officer David Zuby. Toyota's (TM) Highlander earned an "acceptable" rating, while the other six cars that were tested were given a "marginal" or "poor" rating. Reference Link
07:08 EDTQCORDrug deals increase to new high, Bloomberg says
M&A activity in the specialty pharmaceuticals industry has reached a new high after Mallinckrodt (MNK) recently bought Questcor (QCOR) for $5.6B, reported Bloomberg. Drugmakers from Actavis (ACT) to Valeant (VRX) are widening their suites of drugs through takeovers that immediately increased earnings with the help of lower corporate tax rates in countries such as Ireland. Reference Link
06:40 EDTQCORMallinckrodt upgraded to Outperform from Market Perform at BMO Capital
Subscribe for More Information
05:31 EDTQCORQuestcor downgraded to Hold from Buy at Jefferies
Jefferies downgraded Questcor (QCOR) to Hold with an $86 price target following the company's merger agreement with Mallinckrodt (MNK).
April 7, 2014
16:28 EDTQCOROn The Fly: Closing Wrap
Subscribe for More Information
12:15 EDTQCOROn The Fly: Midday Wrap
Subscribe for More Information
11:21 EDTQCOROptions with decreasing implied volatility: QCOR MU KMX EPB
11:05 EDTQCOR High option volume stocks: EXC QCOR SQQQ GNK PPG
Subscribe for More Information
10:40 EDTQCORShort-seller target Questcor spikes after deal to be bought by Mallinckrodt
Questcor (QCOR) shares are sharply higher this morning after the company agreed to be bought by Mallinckrodt (MNK) in a transaction valued at approximately $5.6B. WHAT'S NEW: Questcor, a biopharmaceutical company whose primary drug, H.P. Acthar Gel, is approved by the FDA for the treatment of 19 indications, will be acquired by Mallinckrodt for about $5.6B, made up of $30.00 per share in cash and 0.897 Mallinckrodt shares for each Questcor share they own. The total consideration equated to approximately $86.10 per Questcor share based on the closing price of Mallinckrodt shares on April 4. After the deal closes, Mallinckrodt shareholders will own approximately 50.5% and former Questcor shareholders will own approximately 49.5% of the combined company's stock. The deal is expected to immediately add to Mallinckrodt's fiscal 2014 adjusted earnings per share and significantly add to fiscal 2015 adjusted EPS. The transaction is targeted to close in the third quarter. On the companies' conference call discussing the merger, Questcor said it believes that its first quarter sales will be "somewhat lower" than the fourth quarter of 2013, but also "substantially higher" than last year's first quarter; the consensus estimate for Q1 revenue is $242.08M. Questcor also said that it sees a "favorable" tax structure and operating cash flow, as well as immediate value for shareholders. Mallinckrodt said sees about a 10% decline in the tax rate with the Questcor deal and believes it will realize immediate tax benefits. Mallinckrodt added that its focus will be on deleveraging in the coming months to allow for strategic acquisitions. WHAT'S NOTABLE: Of the 19 indications approved for Acthar, Questcor currently generates substantially all of its net sales from the following on-label indications: the treatment of proteinuria in the nephrotic syndrome of the idiopathic type, or NS, the treatment of acute exacerbations of multiple sclerosis, or MS, in adults, the treatment of infantile spasms, or IS, in infants and children under two years of age, and the treatment of certain rheumatology related conditions. Questcor has been a frequent target of the short-selling blog Citron Research in the past. As recently as March 14, Citron Research claimed Questcor was "deceiving" the FDA and investors, alleging H.P. Acthar Gel's active ingredient is less than 20% of the label specification. PRICE ACTION: Questcor is trading up $11.48, or 16.91%, to $79.35 in mid-morning trading. Meanwhile, Mallinckrodt is down $1.70, or 2.72%, to $60.82.
10:00 EDTQCORQuestcor rises 21.2%
Subscribe for More Information
09:10 EDTQCOROn The Fly: Pre-market Movers
HIGHER: Questcor (QCOR), up 27% after agreeing to be bought by Mallinckrodt (MNK) for cash, stock valued at $86.10 per Questcor share... Agios Pharmaceuticals (AGIO), up 25% after program shows "promising clinical activity" for advanced blood cancers, shares upgraded at JPMorgan... Vocus (VOCS), up 47% after agreeing to be acquired by GTCR for $446.5M, or $18.00 per share... Pandora (P), up 1.3% following upgrade at Wedbush. LOWER: MannKind (MNKD), down 13% after announcing FDA extension of PDUFA date for Afrezza... American Eagle (AEO), down 2.2% following downgrade at Cowen... Pfizer (PFE), down 2.8% after announcing data for palbociclib in metastatic breast cancer... Mattel (MAT), down 3% following downgrade at BMO Capital... WWE (WWE), down 1.2% after cautious mention in Barron's, company announcing WrestleMania 30 grossed $10.9M.
09:00 EDTQCORQuestcor rises 29.2%
Subscribe for More Information
07:16 EDTQCORMallinckrodt and Questcor hold a joint conference call
Subscribe for More Information
07:08 EDTQCORQuestcor to be bought by Mallinckrodt for cash, stock valued at $86.10 per share
Subscribe for More Information
07:04 EDTQCORQuestcor acquired by Mallinckrodt for $5.6B
Subscribe for More Information
06:28 EDTJCPStocks with implied volatility below IV index mean; SWY JCP
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use